Shire to License Global Rights for Pfizer Biologic

Shire_logoPF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The biologic is designed to directly target a gastrointestinal (GI) endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1), that binds to the α4β7 integrin on lymphocytes. Continue reading

Postive Phase III Psoriasis Clinical Trial Results for Pfizer’s Xeljanz

Postive Phase III Psoriasis Clinical Trial Results for Pfizer's XeljanzPfizer have announced positive Phase III clinical trial results for their JAK inhibitor, Xeljanz (tofacitinib).

The results from data taken from two Phase III clinical trials provide additional support for the drug’s use to treat moderate to severe psoriasis.

Pfizer commented that the results from the trials show that both tofacitinib 10mg and 5mg tablets twice daily were superior to placebo in achieving a Physician’s Global Assessment response of “clear” or “almost clear”, in addition to at least a 75% reduction in Psoriasis Area and Severity Index (PASI75).

Continue reading

Pfizer Acquires Baxter’s Vaccines for $635m

Pfizer Acquires Baxter’s Vaccines for $635mPfizer yesterday announced that they have agreed to purchase two of Baxter International’s commercially marketed vaccines and part of Baxter’s production facilities for $635 million.

The purchase will give Pfizer access to Baxter’s meningitis C jab NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis – an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.

Continue reading

Pfizer Announce Positive Preliminary Phase III Clinical Results

Pfizer Announce Positive Preliminary Phase III Clinical ResultsPfizer yesterday announced positive results from their phase III clinical trial comparing prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly, with on-demand treatment for moderately severe to severe hemophilia B.

Top-line results showed that the clinical trial met its primary endpoint, with a statistically noteworthy reduction in the annualised bleeding rate in comparison to on-demand treatment of the drug.

Continue reading

Positive Results for Pfizer’s Lung Cancer Therapy, Xalkori

Postive Results for Pfizer’s Lung Cancer Therapy, XalkoriPfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy.

Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared to standard platinum-based chemotherapy regimens.

Continue reading

Positive Clinical Study Results for Pfizer’s Chantix

Positive Clinical Study Results for Pfizer’s ChantixPfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke.

The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.

Continue reading

Pfizer’s Partners with Scottish Health Boards for New INSPIRE Site

Pfizer’s Partners with Scottish Health Boards for New INSPIRE SiteFour Scottish health boards have partnered up with Pfizer to become the organisation’s second INSPIRE site within the UK, aimed at driving clinical research.

The four health boards are NHS Grampian, Greater Glasgow & Clyde, Lothian and Tayside.

The health boards have already heavily invested in the research endeavour through NHS Research Scotland (NRS), a collaboration involving Scottish NHS Boards and the Scottish government’s Chief Scientist Office.

Continue reading

NICE Draft Recommendation Rejects Pfizer’s Bosulif

Pfizer LogoIt is looking unlikely that Pfizer’s Bosulif (also known as Bosutinib) will be made available on the NHS, after cost regulator, NICE, released preliminary draft guidance rejecting the drug’s use in patients with chronic myeloid leukaemia (CML).

Bosulif has already been approved in Europe as well as the US for use after treatment with one or more tyrosine kinase inhibitor, i.e. Novartis’ Gleevec and Tasigna or Bristol-Myers Squibb’s Sprycel.

Continue reading

Pfizer’s Xeljanz Approved by US FDA

Pfizer LogoPfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday.  The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis.

The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Continue reading